Back to top
more

Addus HomeCare (ADUS)

(Delayed Data from NSDQ)

$109.86 USD

109.86
111,987

-0.71 (-0.64%)

Updated May 14, 2024 04:00 PM ET

After-Market: $109.67 -0.19 (-0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Wall Street Analysts Believe Addus HomeCare (ADUS) Could Rally 27.47%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 27.5% in Addus HomeCare (ADUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

UnitedHealth (UNH) Unit Makes Insulin More Affordable to Avail

by Zacks Equity Research

UnitedHealth Group's (UNH) sub-unit, Optum Rx, resorts to product shift within its formulary and makes the vital medication of insulin cost-effective, thereby boosting patients' access to it.

ADUS or USPH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ADUS vs. USPH: Which Stock Is the Better Value Option?

Does Addus HomeCare (ADUS) Have the Potential to Rally 33.85% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 33.9% in Addus HomeCare (ADUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Addus HomeCare (ADUS) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Addus HomeCare (ADUS) delivered earnings and revenue surprises of 9.52% and 1.71%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad (BIO) Misses Q3 Earnings Estimates, Cuts 2023 View

by Zacks Equity Research

The deterioration in biopharma and early biotech customer spending and a challenging macroeconomic environment in China impact Bio-Rad's (BIO) Q3 performance.

Boston Scientific (BSX) Q3 Earnings Beat, Gross Margin Dips

by Zacks Equity Research

Boston Scientific's (BSX) organic and operational revenues at its respective core business segments and geographies rise in the third quarter.

Edwards Lifesciences (EW) Q3 Earnings Match Mark, Margins Dip

by Zacks Equity Research

Edwards Lifesciences (EW) TMTT performance benefits from the accelerated adoption of the differentiated PASCAL precision platform in the third quarter.

Integra's (IART) Q3 Earnings Miss Estimates, 2023 View Cut

by Zacks Equity Research

The impact of lost revenues and an increase in the return provision related to the Boston product recall dent Integra's (IART) Q3 revenues.

Amedisys' (AMED) Q3 Earnings Miss Estimates, Margins Up

by Zacks Equity Research

The continuous shortage of clinical labor, nursing in particular, is likely to have impacted Amedisys' (AMED) Q3 performance.

Sanghamitra Saha headshot

Can Stocks Enjoy Halloween Effect Despite Rising Rate Fear?

by Sanghamitra Saha

The spooky occasion Halloween can turn into an occasion of angels for Wall Street. Top-ranked sectors like energy, construction, medical and utilities, especially, have the potential to experience a Halloween Effect this year.

Thermo Fisher (TMO) Q3 Earnings Top Estimates, Margins Up

by Zacks Equity Research

Thermo Fisher's (TMO) PPI Business System and strong execution by its global team enabled the company to deliver strong financial performance for Q3.

Amedisys (AMED) Q3 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Amedisys (AMED) delivered earnings and revenue surprises of -9.26% and 0.99%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Quest Diagnostics (DGX) Tops Q3 Earnings, Gross Margin Dips

by Zacks Equity Research

Quest Diagnostics' (DGX) base business growth reflects the company's ongoing efforts to partner with health plans, hospitals and physicians amid a continued return to care.

DaVita's (DVA) Latest Partnership to Improve Kidney Care

by Zacks Equity Research

DaVita's (DVA) new tie-up is likely to enable it to harness Google Cloud's AI and analytics tools to improve care plans and streamline clinical workflows.

ADUS vs. USPH: Which Stock Is the Better Value Option?

by Zacks Equity Research

ADUS vs. USPH: Which Stock Is the Better Value Option?

Zacks.com featured highlights Addus HomeCare, Amalgamated Financial, ALLETE, Arcose and Limbach

by Zacks Equity Research

Addus HomeCare, Amalgamated Financial, ALLETE, Arcose and Limbach have been highlighted in this Screen of The Week article.

Aparajita Dutta headshot

5 Low-Leverage Stocks to Buy as Market Woes Compound

by Aparajita Dutta

The crux of safe investment lies in choosing a company that is not burdened with debt. This is because a debt-free stock is almost impossible to find. You can buy ADUS, AMAL, ALE, ACA and LMB.

Are Investors Undervaluing Addus HomeCare (ADUS) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Humana's (HUM) 2024 MA Plans Promise a Wider Set of Benefits

by Zacks Equity Research

Humana (HUM) aims to expand the reach of its Medicare plans across newer U.S. counties in 2024 through integrating multiple lucrative benefits within them.

ADUS vs. USPH: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ADUS vs. USPH: Which Stock Is the Better Value Option?

Addus HomeCare (ADUS) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Addus HomeCare (ADUS) delivered earnings and revenue surprises of 7% and 1.73%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Addus HomeCare (ADUS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Addus HomeCare (ADUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will High Medical Costs Hurt Molina Healthcare's (MOH) Q2 Earnings?

by Zacks Equity Research

Molina Healthcare's (MOH) Q2 results are likely to reflect the membership growth in its Medicaid and Medicare business units, partly offset by an elevated medical cost level.

Why Addus HomeCare (ADUS) Could Beat Earnings Estimates Again

by Zacks Equity Research

Addus HomeCare (ADUS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.